Novartis has been making significant strides in the bio-tech market with impactful developments. Their recent acquisition of
Avidity Biosciences has significantly bolstered their position, but has also stirred controversy, with the CEO defending the $12 billion deal as an 'appropriate risk to take'. The pharmaceutical giant has also invested $2 billion in
Immunology Biotech Excellergy, marking their second multi-billion-dollar deal within a week. This move signals Novartis' intent to strengthen its Immunology portfolio. Whilst showcasing notable growth despite facing 'historic patent cliffs', Novartis has reassured investors with impressive guidance for 2026 earnings. Following this,
Morgan Stanley has predicted strong price appreciation for Novartis stocks. However, Goldman Sachs has adopted a differing viewpoint, stating that Novartis stocks are overvalued. The company has also been grappling with the increased demand for generics, which has hampered the sales of their blockbuster heart drug. Yet, Novartis remains resilient, securing a US deal potentially shielding it from tariffs, and pursuing aggressive M&A strategies. Past performances have been widely evaluated, with the company's shares hitting an all-time high of $167.87.
Novartis Stocks News Analytics from Thu, 17 Jul 2025 07:00:00 GMT to Thu, 02 Apr 2026 14:53:50 GMT -
Rating 7
- Innovation 8
- Information 8
- Rumor 5
